August 8th 2025
Solutions are emerging to manage advanced modalities and evolving regulatory requirements for viral clearance.
December 5th 2024
Many factors must be considered to overcome the challenges associated with viral clearance.
December 2nd 2022
The design of viral clearance studies must keep pace with the quickly evolving biologic drugs industry.
January 28th 2022
Texcell North America’s new lab facility in Frederick, Md., will expand the CRO’s capabilities in R&D cell culture, viral clearance studies, and viral safety testing.
April 2nd 2021
A series of minute virus of mice spiking studies were performed with a monoclonal antibody product and small-scale AEX membrane adsorbers to evaluate a range of critical processing conditions.
The HSV-1 and HVP-2 titers were determined by the inoculation of test solutions into Vero cell cultures and calculated using the Reed M?ench method.
Viral Filtration of Plasma-Derived Human IgG: A Case Study Using Viresolve NFP
November 1st 2004Human plasma provides a rich source of therapeutic medicines, including gamma globulins, coagulation factors, albumin, alpha anti-trypsin, and others. In 2001, sales of immuno gamma-globulin (IgG) were estimated at $2 billion with a production rate of 50 metric tons for the year.1 A number of new therapeutic products have recently been introduced including Gammimune from Bayer, RhoPhylac from ZLB Behring, and Octagam from Octapharma.
259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831